Remarkably, pathogenic variants in BRCA1/2 were present in patients both with and without clinical benefit, whereas variants in other known homologous recombination repair (HRR) genes were identified exclusively in tumor samples from patients with clinical benefit (ABRAXAS1, FANCA, and RAD51C). This evidence concerns the gene BRCA1 and neoplasm.